Literature DB >> 23923383

Albumin as a drug delivery and diagnostic tool and its market approved products.

Ayesha Sethi1, Muhammad Sher, Muhammad Rouf Akram, Sabiha Karim, Sonia Khiljee, Ashif Sajjad, Syed Nisar Hussain Shah, Ghulam Murtaza.   

Abstract

Albumin is one of the most extensively studied endogenous proteins which are used in the fabrication of drug delivery and diagnostic technologies during last 10 years. This review provides a summary of products involving the use of albumin as a drug delivery tool for getting better the pharmacokinetics of a drug by developing the targetted drug delivery systems and diagnosing the pathologies. Using albumin, following market approved products have been developed: Levemir and Victoza (antidiabetic product), Abraxane (antimetastatic breast cancer product), and Nanocoll and Albures (for lymphoscintigraphy and diagnosis of cancer and rheumatoid arthritis).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23923383

Source DB:  PubMed          Journal:  Acta Pol Pharm        ISSN: 0001-6837            Impact factor:   0.330


  4 in total

1.  In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles.

Authors:  Jessica R Newton-Northup; Marie T Dickerson; Senthil R Kumar; George P Smith; Thomas P Quinn; Susan L Deutscher
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

2.  Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics.

Authors:  Rakesh K Tekade; Muktika Tekade; Manoj Kumar; Abhay S Chauhan
Journal:  Pharm Res       Date:  2014-09-10       Impact factor: 4.200

Review 3.  Albumin Nanovectors in Cancer Therapy and Imaging.

Authors:  Alessandro Parodi; Jiaxing Miao; Surinder M Soond; Magdalena Rudzińska; Andrey A Zamyatnin
Journal:  Biomolecules       Date:  2019-06-05

4.  Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice.

Authors:  Marta Valenza; Jane Y Chen; Eleonora Di Paolo; Barbara Ruozi; Daniela Belletti; Costanza Ferrari Bardile; Valerio Leoni; Claudio Caccia; Elisa Brilli; Stefano Di Donato; Marina M Boido; Alessandro Vercelli; Maria A Vandelli; Flavio Forni; Carlos Cepeda; Michael S Levine; Giovanni Tosi; Elena Cattaneo
Journal:  EMBO Mol Med       Date:  2015-12       Impact factor: 12.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.